Clinical Trials Logo

Distributive Shock clinical trials

View clinical trials related to Distributive Shock.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04904562 Recruiting - Distributive Shock Clinical Trials

Angiotensin II for Distributive Shock

Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of 40 patients who develop distributive shock, intra-operatively or post-operatively within 48 hours of heart transplant or left ventricular assist device placement will be enrolled. Participants will be randomized to Angiotensin II (Giapreza) vs. placebo plus standard of care, as a first line agent for vasoplegia. Two groups of patients will be enrolled: - Group A: Heart Transplant (10 control, 10 treatment) - Group B: LVAD implant (10 control, 10 treatment)

NCT ID: NCT03623529 Recruiting - Septic Shock Clinical Trials

A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Start date: August 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric patients with catecholamine-resistant hypotension (CRH). In addition, this study will evaluate the safety and tolerability of LJPC-501 in pediatric patients, evaluate changes in catecholamine and other vasopressor doses over time, evaluate the change in MAP over time, and the change in Pediatric Logistic Organ Dysfunction-2 (PELOD-2) scores.